1,720,973 research outputs found
La riduzione di noradrenalina endogena potenzia i fenomeni di neurotossicità nel sistema nervoso centrale.
No full textMucoadhesive ophthalmic vehicles: evaluation of polymeric low-viscosity formulations
No full textA series of polyanionic natural or semi-synthetic polymers (polygalacturonic acid, hyaluronic acid, carboxymethylamylose, carboxymethylchitin, chondroitin sulfate, heparan sulfate and mesoglycan) were evaluated as potential mucoadhesive carriers for ophthalmic drugs. Solutions containing cyclopentolate (CY) or pilocarpine (PI) as salts (or polyanionic complexes) with the acidic polymers, all showing a low viscosity, were tested for miotic (resp. mydriatic) activity in albino rabbits. In the case of some polymeric complexes, small but significant increases of the areas under the activity vs. time curves (AUC) over reference cyclopentolate hydrochloride (CYHCl) or pilocarpine nitrate (PINO3) vehicles, and significant AUC decreases after removal bf precorneal mucin by treatment with N-acetylcysteine were observed. A correlation was found between these data, considered indicative of the occurrence of a mucoadhesive interaction ''in vivo'', and ''in vitro'' viscometric data expressing the polymers-mucin force of interaction. The advantages and limitations of the mucoadhesive non-viscous approach in the formulation of ophthalmic vehicles are presented and discussed
Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid
No full textA series of prospective ophthalmic vehicles based on hyaluronic acid (HA) and on polyacrylic acid (PAA) (solutions, gels, matrices prepared by compression and by casting) containing pilocarpine (Pi) or tropicamide (Tr) was evaluated for muco-adhesion, for ocular retention and for biological activity (miosis, mydriasis) in rabbits. The muco-adhesive properties were investigated in vitro using a tensile apparatus with mucin-coated surfaces, while the ocular behviour was estimated visually, using vehicles containing a fluorescent marker. Good to excellent muco-adhesive properties were detected in the HA preparations. The bioavailability-enhancing effect, however, was not very satisfactory with Pi, probably on account of the high solubility and diffusivity of the drug. The effect was more evident with the less soluble drug Tr. The validity of the method used for evaluating bioadhesion, and the relevance of the physicochemical characteristics of the drug to a muco-adhesive ocular delivery system are discussed
PREPARAZIONE E VALUTAZIONE IN VITRO/IN VIVO DI MINIMATRICI OFTALMICHE CONTENENTI TIMOLOLO
No full textThe loss of noradrenergic axons induces a causal effect in different models of experimental Parkinsonism.
No full text
Noradrenergic modulation of methamphetamine-induced striatal dopamine depletion
No full textNoradrenergic (NE) neurons belonging to the locus coeruleus (LC), much more than the A1 and A2 areas, are lost in Parkinson's disease (PD). In this study, we reproduced the selective pattern of NE loss involving axons arising from the LC using the selective neurotoxin N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) (50 mg/kg). In these experimental conditions, we investigated whether NE loss potentiates methamphetamine-induced striatal dopamine (DA) depletion in mice and rats. Administration of a moderate dose of methamphetamine to C57B1/6N mice or Sprague-Dawley rats produced only a partial striatal DA depletion 7 days after drug administration. Pre-treatment with DSP-4, in both animal species, significantly enhanced methamphetamine-induced striatal DA depletion. Administration of a lower dose of methamphetamine did not decrease striatal DA levels when injected alone, but produced a significant decrease in striatal DA when given to DSP-4-pretreated rodents. Moreover, we found that agents reducing the noradrenergic activity (i.e., the alpha-2 agonist clonidine) enhanced, whereas alpha-2 antagonists decreased, methamphetamine toxicity. Enhancement of methamphetamine toxicity did not occur if the noradrenergic lesion was produced 12 hr after methamphetamine administration. By contrast, exacerbation of methamphetamine toxicity in NE-depleted animals was accompanied by increased extracellular DA levels measured with brain dialysis and by a more severe acute DA depletion measured in striatal homogenates
Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice
No full textEvidence is accumulating that norepinephrine depletion enhances the neurotoxic effect of the parkinsonism inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In this study we investigated whether norepinephrine loss potentiates methamphetamine-induced striatal dopamine depletion. Injection of C57BL/6N mice with methamphetamine (2 x 5 mg/kg i.p., at 2-h intervals) produced only a partial (50%) striatal dopamine depletion 7 days after drug administration. Pretreatment with the selective noradrenergic neurotoxin N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4; 50 mg/kg i.p.) enhanced methamphetamine-induced striatal dopamine depletion by 86%, without decreasing striatal dopamine levels when injected alone. Our results extend previous findings obtained with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine in DSP-4-pretreated mic
Region- and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents.
No full textThe neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) is commonly used as a chemical tool to induce selective denervation of noradrenergic terminals arising from the locus coeruleus and to study the molecular mechanisms underlying degeneration of central noradrenergic axons in rodents. Monoamine depletion in different rodent species after DSP-4 is generally assumed to occur with a similar pattern. To verify this assumption, in the present study we evaluated the different patterns of monoamine depletion produced by DSP-4 in different brain regions of two different strains of mice and rats 3, 7 and 14 days after DSP-4 administration. In this report, we show that there are evident species and strain differences concerning the pattern of norepinephrine depletion in various brain regions. Moreover, serotonin levels are fully preserved following DSP-4 in mice, whereas there is a significant serotonin decrease in specific brain regions after the same dose of DSP-4 in rats. Apart from disclosing species and strain variability among rodents in neurotoxin-induced monoamine depletion, these findings suggest that DSP-4 should be considered as a different neurotoxin, depending on the species and strain in which it is administered
- …
